You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

Claims for Patent: 7,361,676

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,361,676

Title:	Solid preparation containing single crystal form
Abstract:	There are provided a solid preparation containing a single crystal of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid, an excipient and a disintegrating agent, and a method for producing the same.
Inventor(s):	Iwai; Michio (Osaka, JP), Nakamura; Kazuhiro (Yamaguchi, JP), Dohi; Masahiko (Tokyo, JP), Mochizuki; Hiroko (Yamaguchi, JP), Mochizuki; Seiji (Yamaguchi, JP)
Assignee:	Teijin Limited (Osaka, JP)
Application Number:	10/503,391
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,361,676
Patent Claims:	1. A tablet comprising crystal A of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid with an X-ray powder diffraction pattern having specific peaks at a reflection angle 2.theta., of 6.62.degree., 7.18.degree., 12.80.degree., 13.26.degree., 16.48.degree., 19.58.degree., 21.92.degree., 22.68.degree., 25.84.degree., 26.70.degree., 29.16.degree. and 36.70.degree., an excipient, and a disintegrating agent, wherein the average particle diameter of the crystal A is from 12.9 .mu.m to 26.2 .mu.m. 2. The tablet according to claim 1, wherein the tablet is prepared by a wet granulating method. 3. The tablet according to claim 1 or 2, wherein said excipient is one or more selected from the group consisting of lactose and partly pregelatinized starch. 4. The tablet according to claim 1 or 2, further comprising hydroxypropyl cellulose as a binder. 5. The tablet according to claim 1 or 2, wherein the tablet is coated with polyethylene glycol. 6. A method for producing the tablet according to claim 2 comprising combining said crystal A of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid with an X-ray powder diffraction pattern having specific peaks at a reflection angle 2.theta., of 6.62.degree., 7.18.degree., 12.80.degree., 13.26.degree., 16.48.degree., 19.58.degree., 21.92.degree., 22.68.degree., 25.84.degree., 26.70.degree., 29.16.degree. and 36.70.degree., an excipient, and a disintegrating agent, wherein the average particle diameter of the crystal A is from 12.9 .mu.m to 26.2 .mu.m. 7. The method for producing a tablet according to claim 6, comprising a step of wet granulating. 8. The method for producing a tablet according to claim 6 or 7, wherein said excipient is one or more selected from the group consisting of lactose and partly pregelatinized starch. 9. The method for producing a tablet according to claim 6 or 7, wherein hydroxypropyl cellulose is added as a binder. 10. The method for producing a tablet according to claim 6 or 7, comprising a step of coating the tablet with polyethylene glycol.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.